Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and Ascites
Open accessAbstract
BACKGROUND: Rifaximin is a non-absorbable antibiotic used to prevent relapses of hepatic encephalopathy which may also be a candidate for prophylaxis of spontaneous bacterial peritonitis (SBP). AIM: To detect the impact of rifaximin on the occurrence and characteristics of SBP. METHODS: We prospectively studied all hospitalized patients that underwent a diagnostic paracentesis in our department from March 2012 to April 2013 for SBP and recorded all clinical data including type of SBP prophylaxis, prior use of rifaximin, concomitant complications of cirrhosis, as well as laboratory results and bacteriological findings. Patients were divided into the following three groups: no antibiotic prophylaxis, prophylaxis with rifaximin or with systemically absorbed antibiotic prophylaxis. RESULTS: Our study cohort comprised 152 patients with advanced liver cirrhosis, 32 of whom developed SBP during the study period. As expected, our study groups differed regarding a history of hepatic encephalopathy and SBP before inclusion into the study. None of the 17 patients on systemic antibiotic prophylaxis developed SBP while 8/27 patients on rifaximin and 24/108 without prophylaxis had SBP (p = 0.02 and p = 0.04 versus systemic antibiotics, respectively). In general, episodes of SBP were similar for patients treated with rifaximin and those without any prophylaxis. However, Escherichia coli and enterococci were dominant in the ascites of patients without any prophylaxis, while mostly klebsiella species were recovered from the ascites samples in the rifaximin group. CONCLUSION: Rifaximin pretreatment did not lead to a reduction of SBP occurrence in hospitalized patients with advanced liver disease. However, the bacterial species causing SBP were changed by rifaximin.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Targeting the gut-microbiota-liver axis reduces spontaneous bacterial peritonitis and hepatic encephalopathy in patients.
“and spontaneous bacterial peritonitis98 and hepatic encephalopathy99 in patients.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Dewhirst, F. E., Chen, T., Izard, J., Paster, B. J., Tanner, A. C. R., Yu, W.-H., Lakshmanan, A., & Wade, W. G. (2010) · Journal of Bacteriology · doi:10.1128/jb.00542-10 · Cited by 3,352 · see citing works
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089 · see citing works
(2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.004 · Cited by 1,726 · see citing works
Rifaximin Treatment in Hepatic Encephalopathy
Bass, N. M., Mullen, K. D., Sanyal, A., Poordad, F., Neff, G., Leevy, C. B., Sigal, S., Sheikh, M. Y., Beavers, K., Frederick, T., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907893 · Cited by 1,300 · see citing works
Ginés, P., Rimola, A., Planas, R., Vargas, V., Marco, F., Almela, M., Forne, M., Miranda, M. L., Llach, J., Salmerón, J. M., et al. (1990) · Hepatology · doi:10.1002/hep.1840120416 · Cited by 627 · see citing works
Fernández, J., Acevedo, J., Castro, M., Garcia, O., de Lope, C. R., Roca, D., Pavesi, M., Sola, E., Moreira, L., Silva, A., et al. (2012) · Hepatology · doi:10.1002/hep.25532 · Cited by 620 · see citing works
Blei, A. T., & Córdoba, J. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03964.x · Cited by 527 · see citing works
García–Tsao, G. (2001) · Gastroenterology · doi:10.1053/gast.2001.22580 · Cited by 466 · see citing works
Gustot, T., Durand, F., Lebrec, D., Vincent, J., & Moreau, R. (2009) · Hepatology · doi:10.1002/hep.23264 · Cited by 439 · see citing works
Bajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060042 · Cited by 430 · see citing works
Pathogenetic mechanisms of hepatic encephalopathy
Häussinger, D., & Schliess, F. (2008) · Gut · doi:10.1136/gut.2007.122176 · Cited by 391 · see citing works
Spontaneous bacterial peritonitis: recent guidelines and beyond
Wiest, R., Krag, A. A., & Gerbes, A. (2011) · Gut · doi:10.1136/gutjnl-2011-300779 · Cited by 384 · see citing works
Tomás, I., Diz, P., Tobías, A., Scully, C., & Donos, N. (2012) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2011.01784.x · Cited by 291 · see citing works
Vlachogiannakos, J., Viazis, N., Vasianopoulou, P., Vafiadis, I., Karamanolis, D. G., & Ladas, S. D. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12070 · Cited by 206 · see citing works
In Vitro Activity and Fecal Concentration of Rifaximin after Oral Administration
Jiang, Z., Shi, K., Palazzini, E., Riopel, L., & DuPont, H. L. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2205-2206.2000 · Cited by 181 · see citing works
Thuluvath, P. J., Morss, S., & Thompson, R. E. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03708.x · Cited by 160 · see citing works
Gillis, J. C., & Brogden, R. N. (1995) · Drugs · doi:10.2165/00003495-199549030-00009 · Cited by 158 · see citing works
Tandon, P., DeLisle, A., Topal, J. E., & Garcia–Tsao, G. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.08.017 · Cited by 158 · see citing works
Zhu, Q., Zou, L., Jagavelu, K., Simonetto, D. A., Huebert, R. C., Jiang, Z.-D., DuPont, H. L., & Shah, V. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.013 · Cited by 144 · see citing works
Appenrodt, B., Grünhage, F., Gentemann, M., Thyssen, L., Sauerbruch, T., & Lammert, F. (2009) · Hepatology · doi:10.1002/hep.23440 · Cited by 133 · see citing works
Self-citationInflammation and hepatic encephalopathy
Coltart, I., Tranah, T. H., & Shawcross, D. L. (2013) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2013.03.016 · Cited by 128 · see citing works
Umgelter, A., Reindl, W., Miedaner, M., Schmid, R. M., & Huber, W. (2009) · Infection · doi:10.1007/s15010-008-8060-9 · Cited by 121 · see citing works
Experimental and Clinical Pharmacology of Rifaximin, a Gastrointestinal Selective Antibiotic
Scarpignato, C., & Pelosini, I. (2006) · Digestion · doi:10.1159/000089776 · Cited by 112 · see citing works
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative
Hoover, W. W., Gerlach, E. H., Hoban, D. J., Eliopoulos, G. M., Pfaller, M. A., & Jones, R. N. (1993) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(93)90004-q · Cited by 100 · see citing works
Nischalke, H. D., Berger, C., Aldenhoff, K., Thyssen, L., Gentemann, M., Grünhage, F., Lammert, F., Nattermann, J., Sauerbruch, T., Spengler, U., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.022 · Cited by 100 · see citing works
Self-citationHanouneh, M. A., Hanouneh, I. A., Hashash, J. G., Law, R. J., Esfeh, J. M., López, R., Hazratjee, N., Smith, T. H., & Zein, N. N. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182506dbb · Cited by 93 · see citing works
DuPont, H. L., & Jiang, Z. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00997.x · Cited by 91 · see citing works
The impact of 16S ribosomal RNA‐based phylogeny on the taxonomy of oral bacteria
Tanner, A. C. R., Maiden, M. F. J., Paster, B. J., & Dewhirst, F. E. (1994) · Periodontology 2000 · doi:10.1111/j.1600-0757.1994.tb00017.x · Cited by 90 · see citing works
Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis
Eltawil, K. M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i8.767 · Cited by 81 · see citing works
Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis
Pelletier, G., Salmon, D., Ink, O., Hannoun, S., Attali, P., Buffet, C., & Etienne, J. P. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90140-m · Cited by 69 · see citing works
Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis
Bunchorntavakul, C. (2012) · World Journal of Hepatology · doi:10.4254/wjh.v4.i5.158 · Cited by 62 · see citing works
Rifaximin intake leads to emergence of rifampin-resistant staphylococci
Valentin, T., Leitner, E., Rohn, A., Zollner‐Schwetz, I., Hoenigl, M., Salzer, H. J. F., & Krause, R. (2010) · Journal of Infection · doi:10.1016/j.jinf.2010.11.004 · Cited by 62 · see citing works
Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin.
Leo, C., Eftimiadi, C., & Schito, G. C. (1986) · PubMed · Cited by 61 · see citing works
Kothary, V., Scherl, E., Bosworth, B. P., Jiang, Z., DuPont, H. L., Harel, J., Simpson, K. W., & Dogan, B. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02163-12 · Cited by 57 · see citing works
Avril, J., Donnio, P.-Y., & Pouedras, P. (1990) · Journal of Clinical Microbiology · doi:10.1128/jcm.28.6.1438-1440.1990 · Cited by 40 · see citing works
Rogers, G. B., Gast, C., Bruce, K. D., Marsh, P., Collins, J. E., Sutton, J., & Wright, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074884 · Cited by 39 · see citing works
Yakar, T., Güçlü, M., Serin, E., & Alışkan, H. E. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0825-1 · Cited by 36 · see citing works
Tamaskar, I., & Ravakhah, K. (2004) · Southern Medical Journal · doi:10.1097/01.smj.0000144616.66917.8a · Cited by 25 · see citing works
Effects of Rifaximin on Bacterial Translocation in Thioacetamide-Induced Liver Injury in Rats
Harputluoglu, M. M. M., Demirel, U., Gül, M., Temel, İ., Gürsoy, Ş., Selçuk, E. B., Aladağ, M., Bilgiç, Y., Gündüz, E., & Seçkın, Y. (2012) · Inflammation · doi:10.1007/s10753-012-9465-2 · Cited by 13 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [24]Gillis JC, Brogden RN (1995) Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutical potential in conditions mediated by gastrointestinal bacteria. Drugs 49: 467– 484. 7774516
Cited by
Sorted by citations
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634 · see citing works
Pierantonelli, I., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 459 · see citing works
Antibiotic prophylaxis in cirrhosis: Good and bad
Fernández, J., Tandon, P., Mensa, J., & García–Tsao, G. (2015) · Hepatology · doi:10.1002/hep.28330 · Cited by 205 · see citing works
Dever, J. B., & Sheikh, M. Y. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13172 · Cited by 204 · see citing works
Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure
Trebicka, J., Bork, P., Krag, A. A., & Arumugam, M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00376-3 · Cited by 203 · see citing works
The challenges of multi-drug-resistance in hepatology
Fernández, J., Bert, F., & Nicolas-Chanoine, M.-H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.006 · Cited by 187 · see citing works
Management of bacterial and fungal infections in cirrhosis: The MDRO challenge
Fernández, J., Piano, S. S., Bartoletti, M., & Wey, E. Q. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.010 · Cited by 170 · see citing works
The Use of Rifaximin in Patients With Cirrhosis
Caraceni, P., Vargas, V., Solà, E., Alessandria, C., de Wit, K., Trebicka, J., Angeli, P., Mookerjee, R. P., Durand, F., Pose, E., et al. (2021) · Hepatology · doi:10.1002/hep.31708 · Cited by 142 · see citing works
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)
Reiberger, T., Püspök, A., Schoder, M., Baumann‐Durchschein, F., Bucsics, T., Datz, C., Dolak, W., Ferlitsch, A., Finkenstedt, A., Graziadei, I. W., et al. (2017) · Wiener klinische Wochenschrift · doi:10.1007/s00508-017-1262-3 · Cited by 137 · see citing works
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications
Ponziani, F. R. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12322 · Cited by 89 · see citing works
Goel, A., Rahim, U. G., Nguyen, L. H., Stave, C. D., & Nguyen, M. H. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14361 · Cited by 80 · see citing works
Novel perspectives in the management of decompensated cirrhosis
Bernardi, M., & Caraceni, P. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0045-2 · Cited by 79 · see citing works
Mandorfer, M., Aigner, E. S., Cejna, M., Ferlitsch, A., Datz, C., Gräter, T., Graziadei, I. W., Gschwantler, M., Hametner‐Schreil, S., Hofer, H., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02229-w · Cited by 69 · see citing works
Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver
Lutz, P. L. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.304 · Cited by 65 · see citing works
Self-citationKASL clinical practice guidelines for liver cirrhosis: Ascites and related complications
(2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2018.1005 · Cited by 65 · see citing works
Use of rifaximin in gastrointestinal and liver diseases
Shayto, R. H., Mrad, R. A., & Sharara, A. I. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i29.6638 · Cited by 57 · see citing works
Suzuki, K., Endo, R., Takikawa, Y., Moriyasu, F., Aoyagi, Y., Moriwaki, H., Terai, S., Sakaida, I., Sakai, Y., Nishiguchi, S., et al. (2017) · Hepatology Research · doi:10.1111/hepr.13045 · Cited by 46 · see citing works
Kamal, F., Khan, M. A., Khan, Z. H., Cholankeril, G. T., Hammad, T. A., Lee‐Smith, W., Ahmed, A., Waters, B., Howden, C. W., Nair, S., et al. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000940 · Cited by 37 · see citing works
Bacterial infections and hepatic encephalopathy in liver cirrhosis–prophylaxis and treatment
Piotrowski, D., & Boroń‐Kaczmarska, A. (2017) · Advances in Medical Sciences · doi:10.1016/j.advms.2016.11.009 · Cited by 36 · see citing works
Kulkarni, A. V., Avadhanam, M., Karandikar, P., Rakam, K., Gupta, A. K., Simhadri, V., Premkumar, M., Zuberi, A. A., Gujjarlapudi, D., Narendran, R., et al. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002575 · Cited by 38 · see citing works
Rifaximin has the potential to prevent complications of cirrhosis
Flamm, S. L., Mullen, K. D., Heimanson, Z., & Sanyal, A. J. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818800307 · Cited by 33 · see citing works
The Role of the Microbiome in Liver Cancer
Moreno‐Gonzalez, M., & Beraza, N. (2021) · Cancers · doi:10.3390/cancers13102330 · Cited by 29 · see citing works
Kutmutia, R., Tittanegro, T., China, L., Forrest, E. H., Kallis, Y. N., Ryder, S. D., Wright, G. A. K., Freemantle, N., & O'Brien, A. J. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001937 · Cited by 28 · see citing works
Li, Y., Yu, Z., Li, A., & Ren, Z. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i28.3555 · Cited by 27 · see citing works
Advances in the pharmacological management of bacterial peritonitis
Pörner, D., von Vietinghoff, S., Nattermann, J., Strassburg, C. P., & Lutz, P. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1915288 · Cited by 26 · see citing works
Self-citationNovel prevention strategies for bacterial infections in cirrhosis
Yan, K. G., & García–Tsao, G. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1145663 · Cited by 26 · see citing works
Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure
Engelmann, C., & Berg, T. (2018) · Visceral Medicine · doi:10.1159/000491107 · Cited by 25 · see citing works
Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome
Ibrahim, E.-S., Alsebaey, A., Zaghla, H., Abdelmageed, S. M., Gamel, K. A. E. M., & Abdelsameea, E. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000967 · Cited by 22 · see citing works
Sidhu, G., Go, A., Attar, B. M., Mutneja, H. R., Arora, S. K., & Patel, S. A. (2017) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2017-000154 · Cited by 19 · see citing works
Gómez‐Hurtado, I., Gimenez, P., García‐Martinez, I., Zapater, P., Francés, R., González-Navajas, J. M., Manichanh, C., Ramos, J. M., Bellot, P., Guarner, F., et al. (2017) · Liver International · doi:10.1111/liv.13551 · Cited by 19 · see citing works
and the INCA trial group, Casper, M., Mengel, M., Fuhrmann, C., Herrmann, E. M., Appenrodt, B., Schiedermaier, P., Reichert, M., Bruns, T., Engelmann, C., et al. (2015) · Trials · doi:10.1186/s13063-015-0594-4 · Cited by 18 · see citing works
Shamseya, M. M., & Madkour, M. A. (2015) · Alexandria Journal of Medicine · doi:10.1016/j.ajme.2015.09.002 · Cited by 15 · see citing works
Goel, A., Biewald, M. A., Huprikar, S. S., Schiano, T. D., & Im, G. Y. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000704 · Cited by 15 · see citing works
Antimicrobial prophylaxis in decompensated cirrhosis: friend or foe?
Crocombe, D., & O'Brien, A. J. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000228 · Cited by 12 · see citing works
Management of Multidrug-Resistant Infections in Cirrhosis
Gallaher, C., & Shawcross, D. L. (2022) · Seminars in Liver Disease · doi:10.1055/a-1765-0056 · Cited by 9 · see citing works
Bitto, N., Ghigliazza, G., Lavorato, S., Caputo, C., & Mura, V. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030934 · Cited by 11 · see citing works
Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota
Méndez‐Sánchez, N., Coronel-Castillo, C. E., Córdova‐Gallardo, J., & Qi, X. (2023) · Antibiotics · doi:10.3390/antibiotics12101475 · Cited by 8 · see citing works
Unresolved issues in the prophylaxis of bacterial infections in cirrhosis patients
Dirchwolf, M., Marciano, S., Martínez, J. E., & Ruf, A. E. (2018) · World Journal of Hepatology · doi:10.4254/wjh.v10.i12.892 · Cited by 7 · see citing works
Samonakis, D. N. (2021) · Annals of Gastroenterology · doi:10.20524/aog.2021.0674 · Cited by 6 · see citing works
Sinkala, E., Zyambo, K., Besa, E. C., Kaonga, P., Nsokolo, B., Kayamba, V. J., Vinikoor, M. J., Zulu, R., Bwalya, M., Foster, G. R., et al. (2018) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.17-0637 · Cited by 4 · see citing works
Una mirada actual a la peritonitis bacteriana espontanea
Cardona, A. H., Guerra, J. J. H., & Restrepo, J. C. (2016) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.56 · Cited by 4 · see citing works
Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use
Nathwani, R., Mullish, B. H., Koeckerling, D., Cole, A., Selvapatt, N., & Dhar, A. (2021) · European Medical Journal · doi:10.33590/emj/21-00026 · Cited by 2 · see citing works
Infection spontanée du liquide d’ascite au cours de la cirrhose
Nousbaum, J. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.07.017 · Cited by 2 · see citing works
Role of Rifaximin in Spontaneous Bacterial Peritonitis Prevention
Oliver, A., Wong, M., & Sanchez, C. (2018) · Southern Medical Journal · doi:10.14423/smj.0000000000000887 · Cited by 2 · see citing works
Zaman, T., Attari, M. B. A., Ahmad, A. N., Butt, M. A., Fayyaz, K., & Zubair, S. A. (2024) · Cureus · doi:10.7759/cureus.55251 · Cited by 1 · see citing works
SÜFFERT, L. C., Pergher, E. A. B., de Abreu, H. S., Abreu, E. S., Beis, L. P. P., Padilha, I. H., Moraes, B. D. F., Passos, P. R. C., Visentini, L. M., Friedrich, F., et al. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102877 · Cited by 1 · see citing works
Spontaneous Bacterial Peritonitis: Is It Still A Life-Threatening Issue in Cirrhosis?
Ribeiro, T. C. D. R. (2016) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2016.05.616 · Cited by 1 · see citing works
SPONTANEOUS BACTERIAL PERITONITIS PROFILE IN DECOMPENSATED CIRRHOTIC EGYPTIAN PATIENTS
SEBAWEH, S., Hamdy, H., Balakosy, A. A., Hussein, H. M., Hassan, M. Y., & Khedr, L. E. (2023) · Journal of the Egyptian Society of Parasitology · doi:10.21608/jesp.2023.297343 · Cited by 1 · see citing works
Ascites: Treatment, Complications, and Prognosis
Huelin, P., Fortea, J. I., Crespo, J., & Fábrega, E. (2017) · InTech eBooks · doi:10.5772/intechopen.70384 · Cited by 1 · see citing works
Editorial: rifaximin—a kick in the gut for spontaneous bacterial peritonitis? Authors’ reply
Goel, A., & Nguyen, M. H. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14450 · Cited by 1 · see citing works
Zhao, J., Zhang, Y., Tian, H., Sun, H., & Liang, C. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14496 · Cited by 1 · see citing works
Leberzirrhose — Update der Therapie
Lutz, P., & Spengler, U. (2015) · CME · doi:10.1007/s11298-015-1207-y
Self-citationSpontaneous Bacterial Peritonitis (SBP)
Schiro, A. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-30103-7_31
Ennaifer, R., Elleuch, N., Cheikh, M., Romdhane, H., Nejma, H. B., & Hadj, N. B. (2015) · Journal Africain d Hépato-Gastroentérologie · doi:10.1007/s12157-015-0606-8
Hu, J., Chang, M.-L., Liu, N., Sung, K., Hsieh, Y., & Chen, C.-H. (2026) · Biomedicines · doi:10.3390/biomedicines14102285
- Authors
- Lutz, P., Parcina, M., Bekeredjian-Ding, I., Nischalke, H. D., Nattermann, J., Sauerbruch, T., Hoerauf, A., Strassburg, C. P., & Spengler, U.
- Affiliations
- University of Bonn (DE)
- Corresponding author
- Lutz, Philipp
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-04-08
- Volume
- 9
- Issue
- 4
- Pages
- e93909
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3979735
- OpenAlex
- W2053677150
- Cited by
- 55
- References
- 39
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 6 · 2020: 1 · 2018: 9 · 2017: 11 · 2016: 7 · 2015: 9
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
- Funders
- Deutsches Zentrum für Infektionsforschung
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Epidemiology › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Keywords
- rifaximin, spontaneous bacterial peritonitis, liver cirrhosis, ascites, antibiotic prophylaxis, systemic antibiotic prophylaxis, Escherichia coli, Klebsiella, Enterococcus, bacterial species composition, hepatic encephalopathy
- MeSH terms
- Rifaximin, Adult, Aged, Aged, 80 and over, Anti-Infective Agents, Ascites, Bacterial Infections, Escherichia coli, Female, Humans, Klebsiella, Liver Cirrhosis, Male, Middle Aged, Peritonitis, Prospective Studies, Rifamycins, Treatment Outcome, Enterococcus, Antibiotic Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
